Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8316957
Reference Type
Journal Article
Title
Novel delivery device for monolithical solid oral dosage forms for personalized medicine
Author(s)
Wening, K; Breitkreutz, J; ,
Year
2010
Is Peer Reviewed?
Yes
Journal
International Journal of Pharmaceutics
ISSN:
0378-5173
EISSN:
1873-3476
Publisher
ELSEVIER SCIENCE BV
Location
AMSTERDAM
Page Numbers
174-181
Language
English
PMID
20635515
DOI
10.1016/j.ijpharm.2010.05.036
Web of Science Id
WOS:000280212500024
URL
https://linkinghub.elsevier.com/retrieve/pii/S0378517310003972
Exit
Abstract
There is an evident need for solid oral dosage forms allowing patients' tailor-made dosing due to variations in metabolization or small therapeutic indexes of drug substances. The objective of this work is the development of a device equipped with a novel solid dosage form, containing carvedilol as model drug, for the delivery of monolithical drug carriers in individual doses. The device was developed and constructed enabling an exact feed rate and dose adjustment by a cutting mechanism. A twin-screw extruder was used for producing cylindrical solid dosage forms. Divided doses were characterized by mass variation, cutting behavior and drug dissolution in order to investigate their applicability for practical use. Different formulations could be extruded obtaining straight cylindrical rods, which are divisible in exact slices by using the novel device. Forces below 20 N were needed to divide doses which comply with pharmacopoeial specification "conformity of mass". The developed formulations exhibit a sustained release of carvedilol within a range from 7 up to 16 h. A novel system consisting of a device and a cylindrical dosage form was developed. Patients' individual doses can be applied as monolithical solid dosage forms for oral use.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity